References on the Administration of Metalloproteinase Inhibitors
Using ALZET^® Osmotic Pumps

Q0871 Fernandez,C.A., Roy,R., Lee,S., Yang,J.A., Panigrahy,D., Van Vliet,K.J., Moses,M.A. The Anti-angiogenic Peptide, Loop 6, Binds Insulin-like Growth Factor-1 Receptor. Journal of Biological Chemistry 2010; 285(-53-):41886-41895. >>> Peptide, loop 6; IP; Mice (SCID); ; Controls received mp w/ PBS; peptides; enzyme inhibitor (metalloproteinase); cancer; Loop 6, anti-angiogenic peptide, is a smaller domain C-terminal portion of TIMP-2.

Q0682 Cirillo,G., Bianco,M.R., Colangelo,A.M., Cavaliere,C., Daniele,D., Zaccaro,L., Alberghina,L., Papa,M. Reactive astrocytosis-induced perturbation of synaptic homeostasis is restored by nerve growth factor. NEUROBIOLOGY OF DISEASE 2011; 41(-3-):630-639. >>> Nerve growth factor, beta, recomb.; GM6001; CSF, artificial; albumin, rat serum; CSF/CNS (intrathecal, subarachnoid space); Rat; 2001; 7 days; Controls received mp w/ vehicle; animal info (Sprague-Dawley, male, 250-300 g); enzyme inhibitor (metalloproteinase); PE10 connected to PE60 tubing.

Q0676 Aagren,M.S., Andersen,T.L., Andersen,L., Schiodt,C.B., Surve,V., Andreassen,T.T., Risteli,J., Franzen,L.E., Delaisse,J.M., Heegaard,A.M., Jorgensen,L.N. Nonselective matrix metalloproteinase but not tumor necrosis factor-alpha inhibition effectively preserves the early critical colon anastomotic integrity. International Journal of Colorectal Disease 2011; 26(-3-):329-337. >>> GM6001; AG3340; DMSO; SC; Rat; 2ML1; ; Controls received mp w/ vehicle; animal info (male Sprague-Dawley, 205-360 g); enzyme inhibitor (matrix metalloproteinase, MMP); 50% DMSO used.

Q0345 Marino,G., Ugalde,A.P., Fernandez,A.F., Osorio,F.G., Fueyo,A., Freije,J.M.P., Lopez-Otin,C. Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2010; 107(-37-):16268-16273. >>> Insulin-like growth factor-1, human, recomb.; HCl; saline, isotonic, sterile; SC; Mice; 1004; 56 days; Animal info (transgenic, Zmpste24 metalloproteinase deficient); long-term study; pumps replaced after 28 days.

P9577 Wright,J.W., Meighan,P.C., Brown,T.E., Wiediger,R.V., Sorg,B.A., Harding,J.W. Habituation-induced neural plasticity in the hippocampus and prefrontal cortex mediated by MMP-3. Behavioural Brain Research 2009; 203(-1-):27-34. >>> MMP-3i; CSF/CNS; Rat; 2001; 6 days; Controls received mp aCSF; functionality of mp verified by residual volume; animal info (male, Sprague Dawley, 300-350g); behavioral testing (head-shake response habituation); cannula placement verified w/icv injection of fast green dye; enzyme inhibitor (metalloproteinase-3).

P9225 Chow,J.P.H., Fujikawa,A., Shimizu,H., Suzuki,R., Noda,M. Metalloproteinase- and gamma-Secretase-mediated Cleavage of Protein-tyrosine Phosphatase Receptor Type Z. Journal of Biological Chemistry 2008; 283(-45-):30879-30889. >>> GM6001; DMSO; CSF/CNS; Mice; 1007D; 4 days; Controls received mp w/ vehicle; enzyme inhibitor (metalloproteinase); ALZET brain infusion kit 3 used; dental cement and stay screws used; animal info (male, C57BL/6, wt, Ptprz -/-, adult); 50% DMSO used.

P9117 Kasaoka,T., Nishiyama,H., Okada,M., Nakajima,M. Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models. CLINICAL&EXPERIMENTAL METASTASIS 2008; 25(-7-):827-834. >>> MMI270; DMSO; PEG 300; SC; Mice; 2004; 2004; 14; 21 days; Comparison of SC injections vs. mp; enzyme inhibitor (matrix metalloproteinase); cancer (melanoma); animal info (7 wks old, BDF1, male, lymphadrectomy; 50% DMSO used; 50% PEG 300.

P8704 Tummalapalli,P., Spomar,D., Gondi,C.S., Olivero,W.C., Gujrati,M., Dinh,D.H., Rao,J.S. RNAi-mediated abrogation of cathepsin B and MMP-9 gene expression in a malignant meningioma cell line leads to decreased tumor growth, invasion and angiogenesis. INTERNATIONAL JOURNAL OF ONCOLOGY 2007; 31(-5-):1039-1050. >>> RNA, small interfering; Mice (nude); 3-4 weeks; Controls received no treatment; cancer (meningioma); animal info (athymic, nude); siRNA plasmid vectors targeting cathepsin B and matrix metalloproteinase MMP9.

P8053 Bruno,M.A., Cuello,A.C. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2006; 103(-17-):6735-6740. >>> Neuroserpin; GM6001; CSF, artificial, PBS; CSF/CNS (parietal cortex); Rat; 2001; 72 hours; Controls received mp w/ vehicle into contralateral side; enzyme inhibitor (tpa, metalloproteinase); multiple pumps per animal (2); animal info (Fischer 344, 6 month old); Lynch coil with air-oil spacer at mp end of tubing; bilateral infusion cannulae; tissue perfusion (parietal cortex).

P7054 Matthey,B., Borchmann,P., Schnell,R., Tawadros,S., Lange,H., Huhn,M., Klimka,A., Tur,M.K., Barth,S., Engert,A., Hansen,H.P. Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo. International Journal of Cancer 2004; 111(-4-):568-574. >>> BB-3644; PBS; SC; Mice (SCID); 2001; 8 days; Controls received mp w/ vehicle; comparison of IV injections vs. mp; enzyme inhibitor (metalloproteinases); cancer (lymphoma); "when BB-3644 was continuously applied via a small osmotic pump, the antitumor activity of a single dose of Ki-3(scFv)-ETA' was further enchanced with a tumor-free survival of all animals treated for more than 200 days." (p. 572).

P7036 Levesque,J.P., Liu,F., Simmons,P.J., Betsuyaku,T., Senior,R.M., Pham,C., Link,D.C. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004; 104(-1-):65-72. >>> MMI270; DMSO; PEG 300; SC; Mice; 6 days; Controls received mp w/ vehicle; functionality of mp verified by serum MMI270 levels; enzyme inhibitor (metalloproteinase).

P6575 Cox,M.J., Hawkins,U.A., Hoit,B.D., Tyagi,S.C. Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation 2004; 109(-17-):2123-2128. >>> CIMP; IP; Mice; 1002; 4 weeks; Controls received no treatment/sham AVF surgery; enzyme inhibitor (metalloproteinase); cardiovascular; peptides; agent also known as (metalloproteinase, cardiac inhibitor).

P6498 Nakamura,E.S., Koizumi,K., Kobayashi,M., Saiki,I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. CANCER SCIENCE 2004; 95(-1-):25-31. >>> MMI270; DMSO; PEG 300; IP; Mice; 2004; 15 days; Controls received mp w/ vehicle; no stress (see pg.27); enzyme inhibitor (matrix metalloproteinase); cancer (lung); MMI270 was formerly termed CGS27023A; 50% DMSO "The continuous administration of MMI270 for 15 days using an osmotic pump led to a significant decrease in the weight of tumor-metastasized lymph nodes" (p. 29).

P6346 Kawai,N., Kawanishi,M., Okada,M., Matsumoto,Y., Nagao,S. Treatment of cold injury-induced brain edema with a nonspecific matrix metalloproteinase inhibitor MMI270 in rats. Journal of Neurotrauma 2003; 20(-7-):649-657. >>> MMI270; DMSO; PEG 300; IP; Rat; 2001D; 2ML1; 7 days; 24 hours; Controls received mp/ vehicle; no stress (see pg. 652); enzyme inhibitor (matrix metalloproteinase); MMI270 is: N-hydroxy-2(R)-[(4-methoxysulfony)(3-picolyl)-amino]-3-metyl butaneamide hydrochloride monohydrate.

P5943 Wada,N., Otani,Y., Kubota,T., Kimata,M., Minagawa,A., Yoshimizu,N., Kameyama,K., Saikawa,Y., Yoshida,M., Furukawa,T., Fujii,M., Kumai,K., Okada,Y., Kitajima,M. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. CLINICAL&EXPERIMENTAL METASTASIS 2003; 20(-5-):431-435. >>> Marimastat; DMSO; water; SC; Mice (SCID); 2002; 2 weeks; controls received mp w/ vehicle; enzyme inhibitor (matrix metalloprotease); marimastat, the broad-spectrum matrix metalloproteinase inhibitor was dissolved in 50% DMSO; angiogenesis inhibitor.

P5454 Charoenrat,P., Rhys-Evans,P., Eccles,S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. International Journal of Cancer 2002; 100(-5-):527-533. >>> Marimastat; DMSO; Water, sterile; SC; Mice; 2002; 17 days; Controls received mp w/ vehicle; cancer; enzyme inhibitor (matrix metalloproteinase).

P5338 Kimata,M., Otani,Y., Kubota,T., Igarashi,N., Yokoyama,T., Wada,N., Yoshimizu,N., Fujii,M., Kameyama,K., Okada,Y., Kumai,K., Kitajima,M. Matrix metalloproteinase inhibitor, marimastat, decreases peritoneal spread of gastric carcinoma in nude mice. Japanese Journal of Cancer Research 2002; 93(-7-):834-841. >>> BE16627B; DMSO; ethylene glycol; SC; Rat; 1003D; 28 days; Controls received mp w/ vehicle; enzyme inhibitor; vehicle mix was 50:50 ratio; BE16627B is a matrix metalloproteinase inhibitor;.

P4382 Conway,J.G., Trexler,S.J., Wakefield,J.A., Marron,B.E., Emerson,D.L., Bickett,D.M., Deaton,D.N., Garrison,D., Elder,M., McElroy,A., Willmott,N., Dockerty,A.J.P., McGeehan,G.M. Effect of matrix metalloproteinase inhibitors on tumor growth and spontaneous metastasis. Clin.Exp.Metastasis 1996; 14(--):115-124. >>> E-64; GI168; GI173; GI179; GI184;; DMSO; Saline; EtOH; Buffer, sodium citrate; Tappsol HPB-20;; SC;; mice;; 2001; 2002;; 2, 7, 14 days;; controls received mp w/ vehicle; cancer; matrix metalloproteinase inhibitors; mice received 2 pumps each; enzyme inhibitors.

P4285 Prescott,M.F., Sawyer,W.K., Von Linden-Reed,J., Jeune,M., Chou,M., Caplan,S.L., Jeng,A.Y. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12, and MMP-13 and on restenosis in rats after balloon injury. Annals of the New York Academy of Sciences 1999/6/30; 878(--):179-190. >>> CGS 27023A;; DMSO; SC;; rat;; 2ML2; 2ML4;; 9-47 days; cardiovascular; enzyme Inhibitor; CGS 27023A is an orally active hydroxamic acid matrix metalloproteinase inhibitor.

P4025 Karran,E.H., Young,T.J., Markwell,R.E., Harper,G.P. In vivo model of cartilage degradation - effects of a matrix metalloproteinase inhibitor. Annals of the Rheumatic Diseases 1995; 54(--):662-669. >>> MI-1; MI-2; Propylene glycol; cartilage, femoral head; rat; 2ML2; 14 days; tissue perfusion (femoral head cartilage); good methods (p. 663); MI-1 and MI-2 are matrix metalloproteinase inhibitors; enzyme inhibitors.

P3379 Conway,J.G., Wakefield,J.A., Brown,R.H., Marron,B.E., Sekut,L., Stimpson,S.A., McElroy,A., Menius,J.A., Jeffreys,J.J., Clark,R.L., McGeehan,G.M., Connolly,K.M. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J.Exp.Med. 1995; 182(--):449-457. >>> GI168; DMSO; Sodium citrate buffer; SC; rat; 2ML2; 2 weeks; controls received mp w/vehicle; dose-response (see p. 451); immunology; multiple pumps per animal (2); "GI168 had poor oral bioavailability and a short plasma t 1/2 after subcutaneous injection... so minipump delivery was evaluated." p. 451; enzyme inhibitor (matrix metalloproteinase).

P2788 Naito,K., Kanbayashi,N., Nakajima,S., Murai,T., Arakawa,K., Nishimura,S., Okuyama,A. Inhibition of growth of human tumor cells in nude mice by a metalloproteinase inhibitor. Int.J.Cancer 1994; 58(--):730-735. >>> BE16627B; Doxorubicin HCl; DMSO; Ethylene glycol; SC; mice (nude); 2001; 2002; 3 weeks, 18 days; controls received vehicle or no treatment; pumps replaced; stress/ adverse reaction: skin inflammation and necrosis around delivery site in mice treated with Adriamycin (pg. 733); BE166278B animals were fine; stability verified for 18 days by assay; cancer; enzyme inhibitor; BE16627B is a metalloproteinase inhibitor; 2002 replaced w/ 2001 after 20 days; adriamycin is doxorubicin HCl.